Lanzillo, R.; Carotenuto, A.; Signoriello, E.; Iodice, R.; Miele, G.; Bisecco, A.; Maniscalco, G.T.; Sinisi, L.; Romano, F.; Di Gregorio, M.;
et al. Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study. J. Clin. Med. 2022, 11, 2081.
https://doi.org/10.3390/jcm11082081
AMA Style
Lanzillo R, Carotenuto A, Signoriello E, Iodice R, Miele G, Bisecco A, Maniscalco GT, Sinisi L, Romano F, Di Gregorio M,
et al. Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study. Journal of Clinical Medicine. 2022; 11(8):2081.
https://doi.org/10.3390/jcm11082081
Chicago/Turabian Style
Lanzillo, Roberta, Antonio Carotenuto, Elisabetta Signoriello, Rosa Iodice, Giuseppina Miele, Alvino Bisecco, Giorgia Teresa Maniscalco, Leonardo Sinisi, Felice Romano, Maria Di Gregorio,
and et al. 2022. "Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study" Journal of Clinical Medicine 11, no. 8: 2081.
https://doi.org/10.3390/jcm11082081
APA Style
Lanzillo, R., Carotenuto, A., Signoriello, E., Iodice, R., Miele, G., Bisecco, A., Maniscalco, G. T., Sinisi, L., Romano, F., Di Gregorio, M., Lavorgna, L., Trojsi, F., Moccia, M., Fratta, M., Capasso, N., Dubbioso, R., Petracca, M., Spiezia, A. L., Gallo, A.,
... Brescia Morra, V.
(2022). Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study. Journal of Clinical Medicine, 11(8), 2081.
https://doi.org/10.3390/jcm11082081
